Prognostic Value of Clinical and CT Features in Camrelizumab Plus Apatinib Treatment for Unresectable Hepatocellular Carcinoma
Clinical and contrast-enhanced show significant prognostic value in patients receiving Camrelizumab plus Apatinib. The developed models may assist in identifying responsive patients and personalizing treatment strategies.
Authors
- Fuling Huang (ORCID: https://orcid.org/0000-0001-9819-5923)
- Liling Long (ORCID: https://orcid.org/0000-0003-3369-8532)
- Jinlian Che
- Weimin Huang (ORCID: https://orcid.org/0000-0002-6691-3369)
- Bin Song (ORCID: https://orcid.org/0000-0002-7269-2101)
- Xialing Huang (ORCID: https://orcid.org/0000-0002-6965-0111)
- Chenhui Li (ORCID: https://orcid.org/0000-0003-3158-9869)
- Ling Zhang (ORCID: https://orcid.org/0000-0003-1155-4802)
- Yingfei Wang (ORCID: https://orcid.org/0000-0002-3634-3617)
- Yidi Chen (ORCID: https://orcid.org/0000-0001-6293-4624)
- Zhiming Zeng
Institutions
- Guangxi Medical University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Guangxi Maternal and Child Health Hospital (CN)
- Sanya Central Hospital (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/jhc.s527624
- Primary Topic
- Radiomics and Machine Learning in Medical Imaging
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China